Recent exon-sequencing studies of human tumours have revealed that subunits of BAF (mammalian SWI/SNF) complexes are mutated in more than 20% of all human malignancies 1,2 , but the mechanisms involved in tumour suppression are unclear. BAF chromatin-remodelling complexes are polymorphic assemblies that use energy provided by ATP hydrolysis to regulate transcription through the control of chromatin structure 3 and the placement of Polycomb repressive complex 2 (PRC2) across the genome 4,5 . Several proteins dedicated to this multisubunit complex, including BRG1 (also known as SMARCA4) and BAF250a (also known as ARID1A), are mutated at frequencies similar to those of recognized tumour suppressors. In particular, the core ATPase BRG1 is mutated in 5-10% of childhood medulloblastomas 6-9 and more than 15% of Burkitt's lymphomas 10,11 . Here we show a previously unknown function of BAF complexes in decatenating newly replicated sister chromatids, a requirement for proper chromosome segregation during mitosis. We find that deletion of Brg1 in mouse cells, as well as the expression of BRG1 point mutants identified in human tumours, leads to anaphase bridge formation (in which sister chromatids are linked by catenated strands of DNA) and a G2/M-phase block characteristic of the decatenation checkpoint. Endogenous BAF complexes interact directly with endogenous topoisomerase IIa (TOP2A) through BAF250a and are required for the binding of TOP2A to approximately 12,000 sites across the genome. Our results demonstrate that TOP2A chromatin binding is dependent on the ATPase activity of BRG1, which is compromised in oncogenic BRG1 mutants. These studies indicate that the ability of TOP2A to prevent DNA entanglement at mitosis requires BAF complexes and suggest that this activity contributes to the role of BAF subunits as tumour suppressors.
Recent exon-sequencing studies of human tumours have revealed that subunits of BAF (mammalian SWI/SNF) complexes are mutated in more than 20% of all human malignancies 1, 2 , but the mechanisms involved in tumour suppression are unclear. BAF chromatin-remodelling complexes are polymorphic assemblies that use energy provided by ATP hydrolysis to regulate transcription through the control of chromatin structure 3 and the placement of Polycomb repressive complex 2 (PRC2) across the genome 4, 5 . Several proteins dedicated to this multisubunit complex, including BRG1 (also known as SMARCA4) and BAF250a (also known as ARID1A), are mutated at frequencies similar to those of recognized tumour suppressors. In particular, the core ATPase BRG1 is mutated in 5-10% of childhood medulloblastomas [6] [7] [8] [9] and more than 15% of Burkitt's lymphomas 10, 11 . Here we show a previously unknown function of BAF complexes in decatenating newly replicated sister chromatids, a requirement for proper chromosome segregation during mitosis. We find that deletion of Brg1 in mouse cells, as well as the expression of BRG1 point mutants identified in human tumours, leads to anaphase bridge formation (in which sister chromatids are linked by catenated strands of DNA) and a G2/M-phase block characteristic of the decatenation checkpoint. Endogenous BAF complexes interact directly with endogenous topoisomerase IIa (TOP2A) through BAF250a and are required for the binding of TOP2A to approximately 12,000 sites across the genome. Our results demonstrate that TOP2A chromatin binding is dependent on the ATPase activity of BRG1, which is compromised in oncogenic BRG1 mutants. These studies indicate that the ability of TOP2A to prevent DNA entanglement at mitosis requires BAF complexes and suggest that this activity contributes to the role of BAF subunits as tumour suppressors.
Using Brg1 floxed/floxed (Brg1 fl/fl ) actin-creER mouse embryonic stem cells (ESCs), we observed that tamoxifen-induced deletion of Brg1 (Brg1 fl/fl (ERD)) results in the appearance of DNA bridges during anaphase ( Fig. 1a ). This phenotype is characteristic of a deficiency in TOP2A function, which normally resolves DNA catenanes that develop during transcription and replication 12 . We determined the frequency of anaphase bridges in Brg1 fl/fl (ERD) cells to be similar to that of cells deficient in other putative tumour suppressors that regulate TOP2A function, including BRCA1, RANBP2 and RECQL5 (refs [13] [14] [15] (Fig. 1a) .
In previous studies, we recovered peptides from TOP2A in mass spectrometric analysis of endogenous BAF complexes 16 . Immunoprecipitation of BAF complexes with antibodies to BRG1 recovered TOP2A and, conversely, immunoprecipitation of TOP2A revealed BRG1 (Fig. 1b ). This association is not dependent on DNA ( Supplementary Fig. 1a, b ). We detected this association in several additional cell types, including mouse embryonic fibroblasts (MEFs) and human embryonic kidney (HEK293T) cells ( Supplementary Fig. 1c ). Brg1 fl/fl (ERD) cells in G1/S using double thymidine block. After release, Brg1 fl/fl and Brg1 fl/fl (ERD) cells transited through the cell cycle at the same rate until reaching G2/M, where the Brg1 fl/fl (ERD) cells exhibited a substantial delay ( Fig. 1c ). In asynchronously dividing cells, this delay resulted in a 1.5-to twofold increase in Brg1 fl/fl (ERD) cells in G2/M ( Fig. 1d ), similar to the treatment of cells with the topoisomerase II inhibitor . Caffeine, an inhibitor of ATM/ATR, forces cells through an ICRF-193-induced decatenation checkpoint 18 and similarly overrides the G2/M arrest in Brg1 fl/fl (ERD) cells ( Fig. 1d ). Furthermore, expression of TOP2A(S1524A) (hereafter TOP2A(SA)), which fails to recruit MDC1 to chromatin upon initiation of the decatenation checkpoint 19 , alleviated the cell cycle delay, suggesting that Brg1 fl/fl (ERD) cells arrest due to activation of the decatenation checkpoint ( Fig. 1e and Supplementary Fig. 1d ). Finally, chromosomes from Brg1 fl/fl (ERD) cells are significantly longer than chromosomes from Brg1 fl/fl cells ( Fig. 1f and Supplementary Fig. 1e ), a defect also observed in TOP2A-deficient cells owing to its role in chromosome condensation 12, 20 . These data indicate that Brg1 deletion resembles the mitotic defects observed with chemical inhibition and/or knockdown of TOP2A 12, 17, 18, 20 . We investigated oncogenic point mutants of BRG1 found in medulloblastoma and Burkitt's lymphoma (BRG1(G1232D), hereafter BRG1(GD); and BRG1(T910M), hereafter BRG1(TM)) 6-11 by expressing Flag-tagged versions in Brg1 fl/fl cells ( Fig. 2a ). The BRG1 mutants were incorporated into the BAF complex normally and did not alter the composition of the complex ( Supplementary Fig. 2a ). Although the T910M mutation is located in the ATP-binding pocket of BRG1, the G1232D mutation is downstream of the helicase superfamily carboxy-terminal (HELICc) domain and thus not obviously involved in ATP turnover ( Fig. 2a ). Subjecting BAF complexes containing BRG1(GD), BRG1(TM), wild-type BRG1 (hereafter WT BRG1) or BRG1(K798R) (hereafter BRG1(KR)) 21 -the ATPase-dead point mutant of BRG1-to an assay for ATPase activity revealed that both cancer mutants are significantly compromised in ATPase activity, although not as profoundly as BRG1(KR) ( Fig. 2b ). BRG1(TM) is more severely compromised than BRG1(GD), which correlated with the viability of the respective cell line ( Supplementary Fig. 2b ).
Cells expressing BRG1(GD) and BRG1(TM), but not WT BRG1, display increases in the percentage of G2/M cells and the incidence of anaphase bridges similar to that of Brg1 fl/fl (ERD) cells ( Fig. 2c, d ). Importantly, expression of the mutants in the presence of endogenous BRG1 gives similar increases, although less severe, in G2/M percentage and anaphase bridge incidence compared to vector cells ( Fig. 2c, d ).
The dominant nature of these mutants on cell cycle and anaphasebridge formation suggests that medulloblastomas with both heterozygous and homozygous mutations in BRG1 have these mitotic defects.
To explore whether the increase in anaphase bridges contributes to increased chromosome instability as it does in TOP2A-deficient cells 12,17 , we analysed ploidy in the BRG1 mutant cell lines. Expression of BRG1(GD) or BRG1(TM) results in a significant increase in cells with .4n DNA content in both ethanol-and tamoxifen-treated cells ( Fig. 2c and Supplementary Fig. 2c ). We also observed a significant increase in the number of BRG1(GD)-and BRG1(TM)-expressing cells with abnormal chromosome number in metaphase spreads from both ethanoland tamoxifen-treated samples ( Fig. 2e ). These data indicate that the G1232D and T910M mutations in BRG1 can contribute to chromosome instability as a result of deficiencies in TOP2A function.
We collected several BRG1 mutant medulloblastomas to determine whether the effects of TOP2A deficiency can be observed in primary tumours. We observed an increased proportion of anaphase bridges in each of five histologic samples from BRG1 mutant tumours relative to controls, suggesting that these tumours have decatenation defects ( Fig. 2f and Supplementary Fig. 2d ). Aneuploidy is common in medulloblastoma and ranges from the partial gain or loss of single chromosomes to full tetraploidy 8,22,23 . However, a recent study showed that the relative rate of tetraploidy of 5 BRG1 mutant tumours was similar to that of 15 BRG1 wild-type tumours 8 . Additional sample characterization will be necessary to definitively assess whether BRG1 mutation causes mitotic defects through insufficient TOP2A function in medulloblastomas.
Microarray analysis of Brg1 fl/fl and Brg1 fl/fl (ERD) ESCs indicated that BRG1-dependent genes are not enriched for Gene Ontology terms related to DNA damage or repair 24 . Additionally, we found no alterations in the abundance, post-translational modifications, cellular localization, or in vitro enzymatic activity of TOP2A in Brg1 fl/fl (ERD) cells (Supplementary Figs 3a-f and 4). To test whether purified BAF complexes could enhance the enzymatic activity of recombinant TOP2A, we used the standard in vitro kinetoplast DNA-based decatenation assay. Immobilized BAF complexes increased the enzymatic activity of TOP2A ( Supplementary Fig. 5a ); however, immunoprecipitated BRG1-mutant BAF complexes also enhanced TOP2A activity, as did immunoprecipitated SUZ12-containing PRC2 complexes, indicating a nonspecific activity on a bare DNA template 25 that does not reflect our in vivo observations. The BRG1 mutants did, however, reduce the association between TOP2A and chromatin, such that more TOP2A 
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remained associated with chromatin after high salt wash in WT BRG1 cells than in BRG1(TM), BRG1(GD) and vector cells ( Fig. 3a and Supplementary Fig. 5b, c) . Reduced binding of TOP2A to chromatin would be expected to compromise TOP2A function and could represent an inability of TOP2A to associate with substrate DNA during decatenation.
To identify defined regions of TOP2A binding across the genome, we performed a TOP2A chromatin immunoprecipitation combined with massively parallel DNA sequencing (ChIP-seq) in Brg1 fl/fl and Brg1 fl/fl (ERD) cells. We recovered very few peaks using traditional ChIP methods, so we used etoposide, a small molecule that freezes TOP2A in a covalent complex with DNA during the enzymatic process, thereby identifying sites of active TOP2A cleavage 26 . We recovered 16,591 TOP2A peaks in Brg1 fl/fl cells and 4,623 TOP2A peaks in Brg1 fl/fl (ERD) cells, demonstrating the contribution of BRG1 to TOP2A binding (Fig. 3b ). Almost two-thirds of the TOP2A Brg1 fl/fl peaks are DNase-I-hypersensitive, consistent with the preference of TOP2A for nucleosome-free DNA 27 . An example reflecting these trends is shown in Fig. 3c . We confirmed TOP2A binding by ChIP-quantitative PCR (qPCR) at 14 BRG1-dependent and 10 BRG1-independent sites in Brg1 fl/fl and Brg1 fl/fl (ERD) cells (Fig. 3d ). In addition, we determined that TOP2A binding is mitigated in BRG1(TM) and BRG1(GD) mutant Brg1 fl/fl (ERD) cells at BRG1-dependent sites (Fig. 3e ). This is not the result of reduced binding of the BRG1 mutants to chromatin, as BRG1(TM) and BRG1(GD) bind similarly to WT BRG1 at these sites ( Fig. 3f) . Given that the BRG1(TM) and BRG1(GD) mutants display reduced ATPase activity, these data implicate a role for the ATPdependent accessibility activity of BAF complexes in TOP2A binding and function across the genome, a function previously identified for yeast protein Snf5 in transcription 28 .
Owing to the dedicated nature of subunits within BAF complexes, TOP2A could be interacting with any BAF subunit. Indeed, we precipitated TOP2A with antibodies to several dedicated subunits as determined by glycerol gradient centrifugation analysis ( Fig. 4a and Supplementary Fig. 6a ). Quantification of the precipitated TOP2A revealed that little TOP2A was recovered after immunoprecipitation with antibodies raised against BAF250a (amino acids 1236-1325) and BAF250b (also known as ARID1B; amino acids 1300-1350), whereas other antibodies immunoprecipitated TOP2A well (Fig. 4a ). We reasoned that the BAF250a/b antibody might disrupt the interaction between TOP2A and the BAF complex if TOP2A bound directly to BAF250a/b. Indeed, TOP2A associated with full-length BAF250a and BAF250a (amino acids 1-1758), but not BAF250a (amino acids 1759-2285) in a heterologous expression system (Fig. 4b ). This interaction is independent of BRG1 because we were unable to detect BRG1 in co-precipitates of BAF250a (1-1758) and TOP2A. Furthermore, the association between TOP2A and BRG1 was lost upon knockdown of BAF250a, with the most severe knockdown resulting in the most severe loss of association ( Fig. 4c and Supplementary Fig. 6b ). To determine whether the interaction between TOP2A and BAF250a was physiologically relevant, we knocked down BAF250a in MEFs and observed frequencies of anaphase bridges and G2/M delay similar to knockdown of Brg1 or Top2a (Fig. 4d, e and Supplementary Fig. 6c, d) . These data indicate that TOP2A associates with BRG1 through a direct interaction with BAF250a.
Our studies point to a new role for ATP-dependent chromatin remodelling in decatenating DNA. Reduced decatenation in vivo is revealed by the frequency of anaphase bridges and an increase in the number of cells in G2/M upon deletion of BRG1 or expression of the tumour-associated T910M and G1232D BRG1 mutants (Figs 1a, d and  2c, d) . Although mitotic defects have been noted in cells lacking BRG1, the cause of these defects was unclear 29 . In addition to BRG1, loss of BAF250a also results in decatenation defects (Fig. 4d, e ), which could reflect the high incidence of mutations in BRG1 and BAF250a in human tumours 1, 23 . Our in vivo observations are reinforced by the requirement of BAF for TOP2A binding at DNase-I-hypersensitive BRG1 binding sites ( Fig. 3b-e ).
The dependence of TOP2A on BAF function offers a possible explanation for the frequency with which BAF subunit mutations are detected in screens for driving mutations in human cancers. Anaphase bridges are often forcibly severed during cytokinesis 30 , resulting in partial or complete chromosome gains or losses as well as polyploidy if the cell fails to undergo mitosis 12, 17 . At present, the number of BRG1-mutant medulloblastomas analysed for ploidy status is insufficient to determine whether BRG1 mutation results in aneuploidy in human tumours. In the case of medulloblastoma, mutations in BRG1 are often accompanied by activating mutations in the WNT signalling pathways and/or MYC amplification 23 . Further studies highlighting these pairings will help define the contribution of reduced TOP2A function as a result of BRG1 mutation to tumorigenesis. 
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METHODS SUMMARY
Brg1 deletion from Brg1 fl/fl creER ESCs and MEFs was performed as previously described 4 . Lentiviruses were produced in HEK293T cells using polyethylenimine transfection. Cells were synchronized using double thymidine block. Cell cycle analysis was performed according to manufacturer instructions (BD Biosciences). TOP2A ChIP-seq was performed following etoposide fixation 26 . qPCR, immunofluorescence, immunoprecipitation and western blotting were done using standard protocols. The chromatin fraction from nuclei incubated in varying concentrations of NaCl was analysed by western blot. essential for embryonic stem cell self-renewal and pluripotency. Proc. Natl Acad. Supplementary Information is available in the online version of the paper. 
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METHODS
Brg1 deletion from Brg1 fl/fl creER ESCs and MEFs was performed as previously described 4 . Lentiviruses were produced in HEK293T cells using polyethylenimine (PEI) transfection. Cells were synchronized using double thymidine block. Cell cycle analysis was performed according to manufacturer instructions (BD Biosciences). TOP2A ChIP-seq was performed following etoposide fixation 26 . qPCR, immunofluorescence, immunoprecipitation and western blotting were done using standard protocols. The chromatin fraction from nuclei in varying concentrations of NaCl was analysed by western blot. Immunofluorescence. To quantify anaphase bridges, cells were fixed with 4% paraformaldehyde for 20 min, washed and stained with 49,6-diamidino-2-phenylindole (DAPI; Sigma). The number of anaphases/telophases with bridges over the total number of anaphases (between 56 and 187 total anaphases per 25-mm slide) was recorded from each slide for more than four independent experiments. Brg1 fl/fl and Brg1 fl/fl (ERD) ESCs were visualized with DAPI 72 h after tamoxifen treatment. Wildtype MEFs were infected with lentiviruses containing short hairpin RNA (shRNA) to Brg1, BAF250a or Top2a and analysed 48-96 h after infection.
To stain for TOP2A and centromeres/microtubules, cells were blocked with 5% BSA/1% goat serum in phosphate buffered saline with 0.1% Tween-20 (PBST) for 1 h following fixation and incubated with anti-centromere (Antibodies Inc.) or anti-c-tubulin (Sigma) and anti-TOP2A (Santa Cruz) for 2 h. After several washes, anti-human Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 were added for 1 h. The cells were then stained with DAPI for 10 min and washed 33 PBS for 10 min each. The coverslips were mounted on slides with Vectashield Hard Mount (Vector Labs).
To quantify anaphase bridges from paraffin-embedded human tumour samples, slides were incubated 2 3 25 min in xylenes, then rehydrated in 100% ethanol, then 95% ethanol, then water, for 2 min each. The slides were boiled in citrate buffer (pH 6.0) (Vector Labs) for 20 min and washed 2 3 5 min in PBS-Tween. The slides were then stained with DAPI for 10 min and washed 3 3 5 min with PBS before mounting with Vectashield Hard Mount. Cell synchronization. ESCs were incubated with 2 mM thymidine for 7-8 h, released into fresh media for 7 h, and then incubated with thymidine again for 7 h. The cells were washed several times with PBS, released into fresh media, and collected at time points thereafter. Cell cycle analysis. The cell cycle analysis was performed using BD Biosciences BrdU-FITC FACS kit. ESCs were incubated with BrdU for 1 h and MEFs were incubated with BrdU for 4 h. Brg1 fl/fl and Brg1 fl/fl (ERD) ESCs were analysed 72 h after tamoxifen treatment. Caffeine was added to media 2 h before BrdU incubation. To determine the per cent of cells in G2/M, DNA was stained with 7-AAD and analysed by FACS. H3(S10)P cell cycle analysis. Brg1 fl/fl ESCs were infected with interference-RNAresistant wild-type human TOP2A or TOP2A(S1524A) and shRNAs to mouse Top2a. Cells were stained with anti-H3(S10)P and analysed by flow cytometry 72 h after treatment with or without tamoxifen. Metaphase spread preparation. MEFs were grown to 85% confluence and incubated for 4 h with colcemid. Cells were collected and swelled by drop-wise addition of 1:1 0.4% KCl/0.4% sodium citrate for 7 min at 37 uC. Cells were then fixed by dropwise addition of 3:1 methanol/acetic acid for 20 min, spun down and fixed for another 30 min. Metaphases were dropped onto slides, dried on wet paper towels and stained with DAPI for visualization. Chromosomes were then measured and counted using ImageJ software. To analyse polyloidy, only cells with greater than 35 chromosomes were counted to eliminate artefacts due to partial spreads. Gene expression profiling and analysis. RNA was isolated using TRIzol (Invitrogen) and reverse transcribed into complementary DNA using Super-Script III reverse transcriptase (Invitrogen). qPCR was performed on the StepOnePlus (ABI) machine using FastStart Universal SYBR Green Master with ROX (Roche). Immunoprecipitation. Nuclei were isolated from cells with buffer A (25 mM HEPES, pH 7.6, 5 mM MgCl 2 , 25 mM KCl, 0.05 mM EDTA, 10% glycerol, 0.1% NP-40) and lysed for 30 min in immunoprecipitation buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% NP-40). The chromatin was removed using centrifugation and the lysates were pre-cleared with 20 ml Protein A or Protein G Dynabeads for 30 min. The protein concentration was quantitated using the bicinchoninic acid (BCA) assay (Pierce) and adjusted to a final volume of 200 ml at a final concentration of 1.5 mg ml 21 with immunoprecipitation buffer. Each immunoprecipitate was incubated with 3 mg of anti-BRG1 (Santa Cruz), anti-TOP2A (Abcam), anti-BAF45d (Crabtree laboratory), anti-BAF47 (Santa Cruz), anti-BAF57 (Bethyl), anti-BAF155 (Crabtree laboratory), anti-BAF60a (BD Transduction Laboratories), anti-BAF250a (Santa Cruz), anti-BAF180 (Bethyl), anti-BAF250b (Santa Cruz, Bethyl), anti-SS18 (Santa Cruz) anti-BAF200 (Santa Cruz) or anti-IgG (Santa Cruz) overnight at 4 uC and then for 2 h with 20 ml
